Key Points about RET-positive Lung Cancer

preview_player
Показать описание
Dr. Justin Gainor discusses what patients need to know about the RET biomarker in lung cancer.

Support for this educational program provided by Amgen, AstraZeneca, Blueprint Medicines, Bristol Myers Squibb, Genentech, Lilly Oncology, Merck, Novartis and Pfizer.
  1. American Lung Association
  2. lung cancer
  3. biomarker testing
  4. ret
  5. fusion
  6. rearrangement
Рекомендации по теме
Key Points about 0:02:10

Key Points about RET-positive Lung Cancer

Key Points about 0:02:47

Key Points about MET in Lung Cancer

Highlights on selpercatinib 0:03:58

Highlights on selpercatinib in RET fusion-positive NSCLC: The LIBRETTO-431 study

[lung] Effect of 0:02:58

[lung] Effect of selpercatinib for RET-positive patients

Targeted Therapy for 0:06:59

Targeted Therapy for Treatment-Naïve RET Fusion-Positive Lung Cancers

ARROW points the 0:07:20

ARROW points the way for RET fusion-positive NSCLC treatment | Stephen Liu

How do ALK-inhibitors 0:02:50

How do ALK-inhibitors work in ALK-positive lung cancer?

Emerging Agents and 0:06:52

Emerging Agents and Combinations to Treat RET Fusion-Positive Lung Cancers

Tell us about 0:03:01

Tell us about RET positive lung cancer

GRACEcast- ASCO LUNG 0:10:19

GRACEcast- ASCO LUNG 2020- New Potential Treatments for MET and RET Positive NSCLC Capmatinib-Tabrec

Rare Fusions in 0:07:37

Rare Fusions in NSCLC: RET - Targeted Therapies in Lung Cancer 2023

RET fusion-positive mNSCLC: 0:02:48

RET fusion-positive mNSCLC: selpercatinib and pralsetinib

Efficacy and safety 0:09:54

Efficacy and safety of selpercatinib in RET fusion-positive cancers other than lung or thyroid c...

Targeting RET in 0:01:45

Targeting RET in lung cancer

RET Fusion Treatment: 0:03:49

RET Fusion Treatment: Selpercatinib - Targeted Therapies in Lung Cancer 2023

The impact of 0:02:12

The impact of selpercatinib in patients with RET fusion-positive NSCLC

RET As a 0:03:31

RET As a Target in Lung Cancer

Linda, a Never-Smoker, 0:02:31

Linda, a Never-Smoker, Diagnosed with RET-positive Lung Cancer in 2020

ARROW update confirms 0:03:18

ARROW update confirms pralsetinib benefit for RET fusion-positive advanced NSCLC | Stephen Liu

Selpercatinib benefit, with 0:06:42

Selpercatinib benefit, with or without pembro, in first-line advanced RET fusion-positive NSCLC

Best New Lung 0:01:11

Best New Lung Cancer Treatments for RET Mutation

LIBRETTO-001: RET-Fusion Positive 0:05:06

LIBRETTO-001: RET-Fusion Positive Metastatic NSCLC

CRSF 7th Masterclass 0:09:02

CRSF 7th Masterclass | First-Line RET Targeted Therapy in Lung Cancer by Dr. Chakor Vora

Selpercatinib Induced Durable 0:01:48

Selpercatinib Induced Durable Efficacy in RET Fusion-Positive NSCLC